Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry G M Heijerman

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Lancet (London, England)|November 5, 2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialHarry G M Heijerman, Edward F McKone, Damian G Downey, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 7, 2018
ECFS best practice guidelines: the 2018 revisionCarlo Castellani, Alistair J A Duff, Scott C Bell, et al.
Science Translational Medicine|June 24, 2016
Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosisJohanna F Dekkers, Gitte Berkers, Evelien Kruisselbrink, et al.
The European Respiratory Journal|July 30, 2016
β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosisLodewijk A W Vijftigschild, Gitte Berkers, Johanna F Dekkers, et al.
Cell Reports|February 14, 2019
Rectal Organoids Enable Personalized Treatment of Cystic FibrosisGitte Berkers, Peter van Mourik, Annelotte M Vonk, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Lancet (London, England)|November 5, 2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialHarry G M Heijerman, Edward F McKone, Damian G Downey, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 7, 2018
ECFS best practice guidelines: the 2018 revisionCarlo Castellani, Alistair J A Duff, Scott C Bell, et al.
Science Translational Medicine|June 24, 2016
Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosisJohanna F Dekkers, Gitte Berkers, Evelien Kruisselbrink, et al.
The European Respiratory Journal|July 30, 2016
β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosisLodewijk A W Vijftigschild, Gitte Berkers, Johanna F Dekkers, et al.
Cell Reports|February 14, 2019
Rectal Organoids Enable Personalized Treatment of Cystic FibrosisGitte Berkers, Peter van Mourik, Annelotte M Vonk, et al.
Pageof 5